What Researchers Did
Researchers conducted a critical review of current therapies for bisphosphonate-related osteonecrosis of the jaw (BRONJ).
What They Found
They found that oral bisphosphonate therapy carries a low risk of ONJ (0.01% to 0.04%), while intravenous administration poses a higher risk (0.8% to 12%). Current BRONJ management is challenging, with no single effective treatment, though long term discontinuation of bisphosphonates and antibiotic therapy for certain stages show some promise.
What This Means for Canadian Patients
Canadian patients receiving bisphosphonate therapy should be aware of the potential for BRONJ, especially with intravenous use. Management remains complex, but discussing long term bisphosphonate discontinuation and antibiotic options with their healthcare provider may be beneficial.
Canadian Relevance
This review does not specifically address Canadian populations or healthcare systems, so direct Canadian relevance is not explicitly stated.
Study Limitations
A significant limitation is the lack of a single, effective treatment for BRONJ, highlighting the ongoing dilemma in its management.